Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Futibatinib and Durvalumab in Cisplatin-Ineligible MIBC Before Cystectomy
NCT06263153Phase 2Recruiting
- Start
- Dec 2024
- Primary completion
- Jul 2027
- Modality
- Antibody Conjugates, Reversible Covalent Inhibitors, Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of futibatinib, durvalumab in muscle-invasive bladder cancer (MIBC). Started Dec 2024; status: recruiting.
02
Drugs
futibatinibdurvalumab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT06263153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06263153.